Immunotherapy Administration and Survival for Stage IV Melanoma Patients at Minority‐Serving Hospitals

Puntos clave

• The research aims to assess how immunotherapy administration affects survival rates in stage IV melanoma patients at minority-serving hospitals.
• Analyzed treatment and survival data for stage IV melanoma patients at minority-serving hospitals.
• Compared immunotherapy access and survival rates between minority-serving and other hospitals.
• Identified institutional factors contributing to disparities in treatment.
• Stage IV melanoma patients at minority-serving hospitals were less likely to receive immunotherapy.
• Patients who did receive immunotherapy had worse survival outcomes compared to those at non-minority-serving hospitals.
• Disparities in access to immunotherapy highlight broader institutional issues.